Jimin Yuan

Dr. Jimin Yuan

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2020 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
JYJimin Yuan
Jimin Yuan
XDXiaoduo Dong
Xiaoduo Dong
JYJiajun Yap
Jiajun Yap
JHJiancheng Hu
Jiancheng Hu
Cancer is characterized as a complex disease caused by coordinated alterations of multiple signaling pathways. The Ras/RAF/MEK/ERK (MAPK) signaling is one of the best-defined pathways in cancer biology, and its hyperactivation is responsible for over 40% human cancer cases. To drive carcinogenesis, this signaling promotes cellular overgrowth by turning on proliferative genes, and simultaneously enables cells to overcome metabolic stress by inhibiting AMPK signaling, a key singular node of cellular metabolism. Recent studies have shown that AMPK signaling can also reversibly regulate hyperactive MAPK signaling in cancer cells by phosphorylating its key components, RAF/KSR family kinases, which affects not only carcinogenesis but also the outcomes of targeted cancer therapies against the MAPK signaling. In this review, we will summarize the current proceedings of how MAPK-AMPK signalings interplay with each other in cancer biology, as well as its implications in clinic cancer treatment with MAPK inhibition and AMPK modulators, and discuss the exploitation of combinatory therapies targeting both MAPK and AMPK as a novel therapeutic intervention.

9 May 2024 in Journal of Controlled Release
Verified
Journal Article
Closed access
JMJingbo Ma
Jingbo Ma
HYHaitao Yuan
Haitao Yuan
JZJingjing Zhang
Jingjing Zhang
XSXin Sun
Xin Sun
LYLetai Yi
Letai Yi
JWJigang Wang
Jigang Wang